DRUG DISCOVERY 15 - ELRIG · Bedside to Bench Target Identification and Target Engagement: Applications in Drug Discovery The Kinetics of Drug-Receptor Binding: Why It Is Important

DRUG DISCOVERY ‘15

2ND - 3RD SEPTEMBER 2015

TELFORD INTERNATIONAL CONFERENCE CENTRE

www.elrig.org

European LaboratoryResearch & Innovation Group

#ELRIGDD15

WELCOME TO DRUG DISCOVERY 2015

We are delighted to welcome you to the 9th annual ELRIG Drug Discovery conference, Drug Discovery 2015 at to our new Telford venue. I hope you will enjoy the excellent conferencing and networking facilities of this venue. We look forward to meeting with you over coffee or beer during the event to get your views on venue, themes, and key issues affecting drug discovery that we can bring into the programme for future years. This Telford & ironbridge region has an amazing heritage of applied innovation - do try to take in the World Heritage Site attractions while you are in the area.

Both myself (Peter & Del) have previously been Drug Discovery conference directors in 2013 and 2014 and we are delighted to welcome Roberto, a great addition to the team for this year; and to acknowledge the great work of Liz Quinn as ELRIG Scientific Program Director in keeping things on track.

The ELRIG Drug Discovery 2015 programme contains a remarkable series of presentations from leading scientists across Europe and beyond, covering advances in basic and translational aspects of drug discovery. The scientific sessions will as usual cover core themes within drug discovery:

Innovation in Assay Development & Screening Chemistry Innovation in Lead Discovery Target Identification & Validation Phenotypic Discovery & Cell Imaging Oncology Drug Targets New Biologic Drugs & Technologies

We are also delighted to introduce two new science sessions this year, firstly a new track on advances in Metabolic and Cardiovascular diseases, which are critical areas for public health around the world. And for the first time we have introduced a track covering the rapidly developing field of Cell & Gene Therapies.

We want to acknowledge the great work of the session chairs in putting together the speaker programmes for these sessions - they have outdone themselves this year with an internationally renowned line-up.We have had some great plenary speakers in recent years, and we are delighted that this year we have secured David Thomas from Montreal, a world-renowned expert in protein trafficking disorders; and Tracy Hussell, head of the unique Manchester Collaborative Centre for Inflammation Research which brings major Pharma and academic experts together to address inflammatory diseases.

Another exciting part of Drug Discovery conference iare the Technology Forums. These were a great success last year, and will again provide a more informal, interactive environment for you to discuss key issues and future directions in workshop-style events coordinated by leaders in the fields. These will address Anti-Infectives; the future of HTS; Enzymology; and Protein-Protein Interactions. Go along and join the discussions!

ELRIG Drug Discovery 2015 will include a high quality scientific poster session, great networking opportunities, and an extensive vendor exhibition - please do quiz the poster presenters, and visit the exhibition to see the range of new products and innovations on display. Don't miss the Innovation Zone, for new and exciting emerging companies and technologies. We are also partnering with the SLAS to bring you a SLAS Author Workshop - a great way to improve your publication skills.

Each year, the ELRIG Drug Discovery conference provides a fantastic communication and learning opportunity for scientists engaged in research fields across drug discovery, bringing together Academia, Biotech, Vendors, & Pharma, into a strong single community of scientists. It is now well established as the leading annual drug discovery event held in the UK. For those of you who have been before, we are glad to see you again; for those of you experiencing DD for the first time - we hope you learn, and have fun, here in Telford.

Regards,

Peter Simpson Del Tresize Roberto Solari

OUR PLENARY KEYNOTE SPEAKERS

SLAS AUTHORS’ WORKSHOP

There is no magic bullet, but there are important tips that every prospective author should know before submitting a scientific manuscript for consideration by a peer-reviewed journal. Julio Martin Plaza, PhD, of GlaxoSmithKline in Tres Cantos, Spain (and member of the Journal of Biomolecular Screening Editorial Board) will share step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication. Attendees will learn what editors want, what they don't want, and how reviewers evaluate manuscripts.

Wednesday September 2nd

Room: Jackfield

Protein trafficking diseases are defined by mutant proteins, that are destined for location at the plasma membrane, but are recognized as misfolded by the cellular protein quality control systems, retained in the endoplasmic reticulum (ER), retrotranslocated into the cytoplasm where it is degraded by the proteasome. Some mutants of secretory proteins are in fact functional if they can be induced to traffic to the cell surface. One example is the F508del-CFTR mutant that, when homzygous, causes most of the cases of cystic fibrosis. Screens for correctors of trafficking of F508del-CFTR have identified molecules that allow its correct cellular trafficking. These correctors fall into two general categories. The first are

“pharmacological chaperones” that bind to the mutant F508del-CFTR molecule and promote its folding so that it escapes the quality control systems. The second are “proteostasis modulators” that act on the cellular quality control systems. While the first category of correctors are specific for the mutant F508del-CFTR molecule some of the second category of proteostasis modulators can correct the trafficking of mutant proteins of other protein trafficking diseases.

Alveolar macrophages exist in a unique microenvironment and, despite historical evidence showing that they are in close contact with the respiratory epithelium, have until recently been investigated in isolation. The microenvironment of the airway lumen has a considerable influence on many aspects of alveolar macrophage phenotype, function and turnover. As the lungs adapt to environmental challenges, so too do alveolar macrophages adapt to accommodate the ever-changing needs of the tissue. I will discuss how working in an open innovation, pre-competitive environment with the UK’s largest pharmaceutical companies allows us to explore the unique characteristics of alveolar macrophages, the mechanisms that

drive their adaptation and the direct and indirect influences of epithelial cells on them. I will also highlight how they adapt in the inflamed lung and the processes driving adaptation in a variety of inflammatory conditions. The unique tissue location and function of alveolar macrophages distinguish them from other macrophage populations. However, over-regulation of them in repair leads to bacterial exacerbations. Re-setting the inflammatory tone of the airspaces and particularly airway macrophages presents new therapeutic opportunities.

Professor Tracy HussellDirector of the Manchester Collaborative Centre for Inflammation Research (MCCIR).

The Development of New Therapeutics for respiratory inflammationIronbridge room - 14.00 - Thursday 3rd September

Dr. David ThomasCEO, Traffick Therapeutiques/Thérapeutiques, Inc

Tackling Protein Trafficking DiseasesIronbridge room - 14.00 - Wednesday 2nd September

OUR SCIENTIFIC COMMITTEE

Metabolic & Cardiovascular Drug Discovery Chemistry Innovation In Lead Discovery

Target Identification & Validation Innovation In Assay Development & Screening

Oncology Drug Targets Cell And Gene Therapy

New Biological Drugs & Technologies Phenotypic Discovery & Cell Imaging

Marcus SchindlerAstraZeneca R&D Mölndal

Paul WyattUniversity of Dundee

Michael SchneiderImperial College London

Darren McKerrecherAstraZeneca

Jon MooreHorizon Discovery

Anne PhelanPfizer Neusentis

Hamish RyderCancer Research Technology

Angela GrittiSan Raffaele Telethon Institute

for Gene Therapy (TIGET)

Lutz JermutusMedImmune

Marc BickleMax Planck Institute of

Molecular CellBiology & Genetics

Rachel Grimley AstraZeneca

Steve HillUniversity of Nottingham

Herbie NewellNewcastle University

Aniz GirachNightstaRx

Katy KettleboroughMRC Technology

Steve LudbrookGlaxoSmithKline

PROGRAMME AT A GLANCE

Plenary Keynote: Tackling Protein Trafficking Diseases

Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial

Infarction

Unravelling the Molecular Mechanisms of

Proteinuria

Nanotechnology, Imaging and Targeted Drug Therapy

in Cardiac Pathology

The Role of Post-Transcriptional

Regulation in Cardiac Disease

Myocyte Lipotoxicity: A Chemical Biology

Approach

Synthetic Chemically Modified mRNA (modRNA): Towards A New Technology Platform for

Cardiovascular Biology & Medicine

Plenary Keynote: The Development of New Therapeutics for respiratory inflammation

Design of Novel Building Blocks to Enhance Drug

Discovery

Phenotypic Drug Discovery: With A Lot of Help From Our

Friends!

Structure-Kinetic Relationships: Investigating the Molecular

Basis for Optimising Drug-Target Residence Time

All in Good Time, Exploiting Residence Time to Improve

Fragment Based Drug Discovery

Phage Selection of Bicyclic Peptides for Therapeutic

Application

Using Diversity-Oriented Synthesis to Enable

Fragment-Based Lead Discovery

The Role of Systems Biology / Pharmacology in Choosing and

Validating Targets

Mass Spectrometry-Based Discovery Tools for

Epigenetics

The Impact of CRISPR/Cas9 on Target Identification and

Validation

The Application of Synthetic Lethality to Cancer Treatment

New Targets for Virus-Induced Asthma Exacerbations: From

Bedside to Bench

Target Identification and Target Engagement: Applications in

Drug Discovery

The Kinetics of Drug-Receptor Binding: Why It Is Important and How We Can Measure It

Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased µ Opioid

Receptor Agonists

Efficacy and Toxicity Assays Using iPS Cells - Utilising Cells

Reset to the Manufacturers Default Setting

Functional Screening of Network Activity in Primary Neuronal

Cultures Using a Novel Phenotypic Assay Platform

Nanobodies in Cell-Based Screening

Phenotypic Screening for Novel Druggable Targets

Using "Protein-Interference"

Optimising Oncology Drug Discovery via Partnerships

Between Academia and Industry

Building On an Atypical (PKC) Relationship –

Innovative Drug Discovery Alliances in Oncology

Targeting Oxygenases for the Regulation of Protein

Biosynthesis

Chemical Probes for the Bromodomain of the BRPF

Family

Fragment-Based Lead Generation of Reversible

Inhibitors for Lysine-Specific Demethylases

“We Must Work Together To Catalyse the Generation of

More Novel and More Affordable Cancer Treatments”

Modelling Cardiovascular Disease with Pluripotent Stem

Cells: a High-Content Approach

Accelerating Human iPSC in vitro Disease Modeling by Introducing

Targeted Gene Mutations in Isogenic Cell Lines Through the CRISPR/Cas9 Nuclease System

Adoptive T cell Therapy for Cancer

Hematopoietic Stem Cell Based Gene Therapy for the Treatment of Lysosomal Storage Disorders

Gene Therapy for Choroideremia, an Inherited

Cause of Blindness

How Stem Cells Signal to Host Immune Cells

Development of Cytotoxic Bicyclic Peptide Drug

Conjugates and Applications in Molecular Targeted Cancer

Therapy

How Information From the Study of Antibody Function Can

be Used in the Discovery of Novel Small Molecule

Therapeutics

XTEN Protein Polymer for Half-Life Extension and Tumor

Drug Delivery

Fine-Tuned T Cell Receptors for Cancer

Immunotherapy

PBD-Based Antibody Drug Conjugates

Towards a New Class of Biotherapeutics Based on

Synthetic Genetic Polymers

Increasing Physiological Relevance, Increasing

Information: High-Content Phenotypic Screening

Compound Screening and Profiling in Cultured Human

Tissues

Mass Spectrometry Imaging in Drug Discovery – Bridging Between Cells and Tissues

Phenotypic Discovery Using Machine Learning and Image

Analysis Methods

KNIME Image Processing - Integrative Open-Source

BioImage Analysis

Phenotypic Screening to Identify Novel Targets for

Discovery

Metabolic & Cardiovascular Drug Discovery

Chemistry Innovation In Lead Discovery

Target Identification& Validation

Innovation In AssayDevelopment & Screening

Oncology Drug Targets Cell And Gene Therapy New Biological Drugs& Technologies

Phenotypic Discovery& Cell Imaging

Day

1: W

edne

sday

2nd

Sep

tem

ber

Day

2: T

hurs

day

3rd

Sept

embe

r

SESSION SUMMMARY

17:00 - 18:00

Introduction and Welcome

COFFEE BREAK

POSTER TASTERS

SNAPSHOT PRESENTATIONS

POSTER SESSION

NETWORKING - DRINKS RECEPTION - DRAGON’S DEN

LUNCH - EXHIBITION - POSTERS


Room: Pattingham

TIME SPEAKER TITLESession Chairs

PLENARY KEYNOTE: ROOM - IRONBRIDGE

Tackling Protein Trafficking DiseasesDr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc

METABOLIC & CARDIOVASCULAR DRUG DISCOVERY

Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial Infarction

Unravelling the Molecular Mechanisms of Proteinuria

Nanotechnology, Imaging and Targeted Drug Therapy in Cardiac Pathology

The Role of Post-Transcriptional Regulation in Cardiac Disease

Myocyte Lipotoxicity: A Chemical Biology Approach

Cardiovascular and metabolic disorders are the predominant cause of death of disability in the industrialized world and increasingly prevalent in developing nations. Here, we address unmet needs and therapeutic opportunities including: a chemical biology approach to muscle cell lipotoxicity; human stem cell-derived cardiomyocytes as a platform for target validation in suppressing cardiac muscle cell death; genetics, genomics, and epigenomics of metabolism; signalling networks in glomerular kidney disease; nanotechnology and drug delivery; and chemically modified mRNA, a new technology for drug discovery and therapeutics.

Katie ChapmanDomainex

Tobias HuberUniversity of Freiburg

Kim KellyUniversity of Virginia

Norbert HübnerMax-Delbrück-Center for Molecular Medicine (MDC)

Keynote Speaker: Daniel P. KellySanford Burnham Prebys Medical Discovery Institute

CHAIRS: Michael Schneider, Imperial College London. Marcus Schindler, AstraZeneca R&D Mölndal

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:50

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 18:00

16:00 - 16:30

Synthetic Chemically modified mRNA (modRNA): Towards A New Technology Platform for Cardiovascular Biology and Medicine

Ken ChienKarolinska Instituet

Afrah Sattikar, MRC TechnologyLaurent Brault, Exquiron

LabLogic, Hamamatsu Phonics UK Limited

13:50 - 14:00 Welcome words from the ELRIG Chairman - Sanj Kumar - IRONBRIDGE

Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.

#ELRIGDD15

SESSION SUMMARY

17:00 - 18:00


COFFEE BREAK

POSTER TASTERS


POSTER SESSION




Room: Beckbury



CHEMISTRY INNOVATION IN LEAD DISCOVERY

Design of Novel Building Blocks to Enhance Drug Discovery

Phenotypic Drug Discovery: With A Lot of Help From Our Friends!

Structure-Kinetic Relationships: Investigating the Molecular Basis for Optimising Drug-Target Residence Time

All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery

Phage Selection of Bicyclic Peptides for Therapeutic Application

Using Diversity-Oriented Synthesis to Enable Fragment-Based Lead Discovery

Frederick GoldbergAstraZeneca

Paul WyattUniversity of Dundee

Tackling Protein Trafficking Diseases

Mike WaringAstraZeneca

James MurrayVernalis (R&D) Ltd

Christian HeinisEcole Polytechnique Fédérale de Lausanne (EPFL)

Keynote Speaker: Damian YoungBaylor College of Medicine

Dr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc

The need to create chemical leads for ever more challenging biological targets has led to a need for increased chemical innovation in lead discovery. Recent innovations include the generation of high quality hits outside classical ‘small molecule’ chemical space, the application of emerging synthetic methods and design principles to deliver diverse compound libraries, and greater consideration of conformational and kinetic profiles of potential hits. This session will highlight scientific approaches that increase chemical innovation in lead discovery which, together with novel partnership approaches, may deliver high quality leads for today’s challenging drug targets.

CHAIRS: Darren McKerrecher, AstraZeneca. Paul Wyatt, University of Dundee

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:50

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 18:00

16:00 - 16:30

Daniela Natale, IRBM Science Park, SpaFiona Jeganathan, Institute of Cancer Research

Lab Services, EpiSentec



#ELRIGDD15

SESSION SUMMMARY

17:00 - 18:00


COFFEE BREAK

POSTER TASTERS


POSTER SESSION




Room: Wenlock

TIME SPEAKER TITLE

Session Chairs


The Role of Systems Biology / Pharmacology in Choosing and Validating Targets

Mass Spectrometry-Based Discovery Tools for Epigenetics

The Impact of CRISPR/Cas9 on Target Identification and Validation

The Application of Synthetic Lethality to Cancer Treatment

New Targets for Virus-Induced Asthma Exacerbations: From Bedside to Bench

Target Identification and Target Engagement: Applications in Drug Discovery

Neil BensonXenologiq

Pete DiMaggioImperial College London


Jon MooreHorizon Discovery

Chris LordInstitute of Cancer Research

Michael EdwardsImperial College London

Keynote Speaker: Friedrich Reinhard Cellzome


TARGET IDENTIFICATION & VALIDATION

CHAIRS: Rachel Grimley, AstraZeneca Jon Moore, Horizon Discovery

The high levels of investment in pharmaceutical R&D over the past decade have not correlated with the number of NMEs gaining approval. Whereas poor PK/PD properties used to be the primary cause of attrition, most New Molecular Entities (NMEs) vs novel targets now fail due to lack of efficacy and/or safety in patient studies. So how can we assure that the right target is selected at the beginning of a drug discovery campaign? And how can we ensure validation enables translation into the clinic? This session covers a range of methodologies and case studies describing key approaches to address these questions.

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:50

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 18:00

16:00 - 16:30

Emma Shanks, CRUK Beatson InstituteHelen Boyd, AstraZeneca

NMI (Natural and Medical Sciences Institute), LabCyte, Promega, Molecular Devices



#ELRIGDD15

SESSION SUMMARY

17:00 - 18:00


COFFEE BREAK

POSTER TASTERS


POSTER SESSION




Room: Ironbridge

TIME SPEAKER TITLE

Session Chairs


The Kinetics of Drug-Receptor Binding: Why It Is Important and How We Can Measure It

Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased µ Opioid Receptor Agonists

Efficacy and Toxicity Assays Using iPS Cells - Utilising Cells Reset to the Manufacturers Default Setting

Functional Screening of Network Activity in Primary Neuronal Cultures Using a Novel Phenotypic Assay Platform

Nanobodies in Cell-Based Screening

Phenotypic Screening for Novel Druggable Targets Using "Protein-Interference"

Steven CharltonUniversity of Nottingham

David WinpennyPfizer Neusentis


Julie HolderRoslin Cells Limited

Mattias KarlssonCellectricon AB

Miguel CondeAblynx

Keynote Speaker: Chris TorrancePhoreMost Ltd


CHAIRS: Steve Hill, University of Nottingham. Anne Phelan, Pfizer Neusentis

In recent years, drug discovery has moved towards more complex assay technologies that address questions of direct relevance to human disease. These include: (1) the use human stem cell technologies for drug screening, (2) the establishment of high throughput assays that allow drug discovery to be informed by ligand-binding kinetics, (3) the evaluation of methodologies to exploit the clinical potential of ligand bias, (4) platform technologies to rapidly scan disease pathways for novel drug targets. The Innovation in Assay Development & Screening session at ELRIG Drug Discovery 2015 will cover major developments in this fast moving field.

INNOVATION IN ASSAY DEVELOPMENT & SCREENING

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 13:50

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 18:00

16:00 - 16:30

Rebecca Dixon-Steele, AstraZenecaMark Soave, Nottingham University

Essen Bioscience, Tecan, Sygnature Discovery, Caltag Medsystems, Celenys



#ELRIGDD15

SESSION SUMMMARY


COFFEE BREAK

POSTER TASTERS



Thursday September 3rd

Room: Pattingham

TIME SPEAKER TITLE

Session Chairs

Optimising Oncology Drug Discovery via Partnerships Between Academia and Industry

Building On an Atypical (PKC) Relationship – Innovative Drug Discovery Alliances in Oncology

Targeting Oxygenases for the Regulation of Protein Biosynthesis

Chemical Probes for the Bromodomain of the BRPF Family

Fragment-Based Lead Generation of Reversible Inhibitors for Lysine-Specific Demethylases

“We Must Work Together To Catalyse the Generation of More Novel and More Affordable Cancer Treatments”

Neil ThompsonAstex Pharmaceuticals

Christian DillonCancer Research Technology Discovery Laboratory

Christopher SchofieldOxford University

Paul FishUCL School of Pharmacy

Ulf BrembergBeactica

Keynote Speaker: Chas BountraSGC, University of Oxford

ONCOLOGY DRUG TARGETS

The translation of emerging knowledge of cancer biology into novel therapies remains a great challenge in drug discovery, and requires early collaboration between key stakeholders in academia and industry to ensure that the most relevant and actionable targets are taken forward. This session will focus on academia-industry collaboration models established in recent years, with sharing of examples of successful outcomes and lessons learned. A secondary focus will be on epigenetic mechanisms in cancer where pioneering work from organizations such as the Structural Genomics Consortium, has revealed a large number of potentially druggable proteins involved in the writing, reading and erasure of epigenetic marks.

CHAIRS: Herbie Newell, Newcastle University. Hamish Ryder, Cancer Research Technology

PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for Respiratory Inflammation

Professor Tracy HussellManchester Collaborative Centre forInflammation Research

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 14:00

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 17:00

16:00 - 16:30

CLOSE OF CONFERENCE - with prize draw - IRONBRIDGE

Rachel McMenamin, Mission TherapeuticsAhmad Kamal, MRC Technology

Cisbio, Perkin Elmer


#ELRIGDD15

SESSION SUMMARY

COFFEE BREAK

POSTER TASTERS




Room: Beckbury

TIME SPEAKER TITLE

Session Chairs

Modelling Cardiovascular Disease with Pluripotent Stem Cells: a High-Content Approach

Accelerating Human iPSC in vitro Disease Modeling by Introducing Targeted Gene Mutations in Isogenic Cell Lines Through the CRISPR/Cas9 Nuclease System

Adoptive T cell Therapy for Cancer

Hematopoietic Stem Cell Based Gene Therapy for the Treatment of Lysosomal Storage Disorders

Gene Therapy for Choroideremia, an Inherited Cause of Blindness

How Stem Cells Signal to Host Immune Cells

Gabor FoldesNational Heart and Lung Institute, Imperial College London

Vania BroccoliItalian Research Council (CNR) and Ospedale San Raffaele

David GilhamInstitute of Cancer Sciences,Manchester University

Alessandra BiffiTIGET, IRCCS San Raffaele Scientific Institute

Alun BarnardOxford University

Keynote Speaker: Stefano Pluchino Wellcome Trust-MRC Stem Cell Institute, University of Cambridge (UK)

CHAIRS: Aniz Girach, NightstaRx. Angela Gritti, San Raffaele Telethon Institute for Gene Therapy (TIGET)

Gene- and cell-based therapies are fast-growing forms of personalized medicine that rely on steady advances in gene transfer technologies, stem cell manipulation and the growing capacity for genetic reprogramming of mammalian cells. They may fulfill the promise of safe and effective therapies for currently untreatable diseases. The session will describe the latest developments and the crucial challenges for this field, touching on basic science, pre-clinical and clinical studies, with an emphasis on gene therapy approaches for blood, ocular and neurodegenerative disorders, and with a special insight in novel approaches aimed to generate transplantable neuronal populations from induced pluripotent stem cells.

CELL AND GENE THERAPY



9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 14:00

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 17:00

16:00 - 16:30



Vasco Meneghini, San Raffaele Telethon Institute for Gene Therapy (TIGET)

Chemometec A/S, Cambridge Bioscience Limited, QuantaCell, PAA


#ELRIGDD15

SESSION SUMMMARY

9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 14:00

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 17:00

16:00 - 16:30


COFFEE BREAK

POSTER TASTERS





Room: Wenlock



Development of Cytotoxic Bicyclic Peptide Drug Conjugates and Applications in Molecular Targeted Cancer Therapy

How Information From the Study of Antibody Function Can be Used in the Discovery of Novel Small Molecule Therapeutics

XTEN Protein Polymer for Half-Life Extension and Tumor Drug Delivery

Fine-Tuned T Cell Receptors for Cancer Immunotherapy

PBD-Based Antibody Drug Conjugates

Towards a New Class of Biotherapeutics Based on Synthetic Genetic Polymers

Dan Teufel Bicycle Therapeutics

Tom CrabbeUCB

The Development of New Therapeutics for Respiratory Inflammation

Volker SchellenbergerAmunix

Bent JakobsenAdaptimmune

John HartleyUniversity College London

Keynote Speaker: Philipp HolligerMRC Laboratory of Molecular Biology


CHAIRS: Katy Kettleborough, MRC Technology. Lutz Jermutus, MedImmune

NEW BIOLOGICAL DRUGS & TECHNOLOGIES

The continuing success of biological drugs, in particular monoclonal antibodies but increasingly also other modalities such as peptides, conjugates and multi-selective agents, will be considered in this session. Alongside this, technologies for discovering, optimising and characterising biopharmaceuticals will be discussed. The session will also explore the interface between biological and small molecule drugs: can information from biological drugs help us design better small molecule drugs? how are drugs at the interface of both areas, such as cyclic peptides and small molecule conjugates to peptides, proteins and antibodies, defining novel drug classes?

Basma Al-Sudani, Salford UniversityLaurent Brault, Exquiron

Greiner Bio-One, SAL Scientific Limited, NanoTemper, Technologies GmbH, Stratech Scientific


#ELRIGDD15

SESSION SUMMARY


COFFEE BREAK

Increasing Physiological Relevance, Increasing Information: High-Content Phenotypic Screening

Compound Screening and Profiling in Cultured Human Tissues

POSTER TASTERS


Mass Spectrometry Imaging in Drug Discovery – Bridging Between Cells and Tissues

Phenotypic Discovery Using Machine Learning and Image Analysis Methods

KNIME Image Processing - Integrative Open-Source BioImage Analysis

Phenotypic Screening to Identify Novel Targets for Discovery


Anne CarpenterBroad Institute of Harvard and MIT

Leo PriceOcellO

Peter WebbornAstraZeneca R&D

Peter HorvathBiological Research Centre of the Hungarian Academy of Sciences

Christian DietzUniversity of Konstanz

Keynote Speaker: Stephen Rees AstraZeneca


Room: Ironbridge


PHENOTYPIC DISCOVERY & CELL IMAGING

The renaissance in the use of phenotypic cell-based assays throughout the drug discovery process is an opportunity to combine an approach used intensively in the pre-genomic area with enabling new technologies. Success in the area aligns drug discovery hypotheses with translational disease biology, leading to an anticipated improvement in attrition rates of new medical entities in the clinic. Cellular imaging is a broad field that is being utilised to deliver multiple phenotypic assay opportunities in drug discovery programs (including simple to complex cell cultures, data analysis, and biomarker/phenotype detection), and is advancing rapidly. The Phenotypic discovery and cellular imaging session at ELRIG Drug Discovery 2015 will cover progress in imaging technologies, analytics and cell biology in this lively and quickly progressing field.

CHAIRS: Steve Ludbrook, GlaxoSmithKline. Marc Bickle, Max Planck Institute of Molecular Cell Biology & Genetics



9:15 - 10:00

9:10 - 9:15

10:30 - 11:00

10:00 - 10:30

11:00 - 11:30

11:30 - 12:00

12:30 - 14:00

12:00 - 12:30

14:00 - 15:00

15:00 - 15:30

15:30 - 16:00

16:30 - 17:00

16:00 - 16:30


Daniel Wilcock, AstraZenecaThalia Carreno, University of Sussex

Genedata, IntelliCyt, PhaseFocus, HighRes Biosolutions, Bio Tek Instruments


#ELRIGDD15

TECHNOLOGY FORUMS

This session contains four workshops, set in the round to promote discussion and debate within each topic area. There will be a chair leading the discussion, but your participation is very much encouraged. Please come along and join in the discussions.

CHAIRS: Eddy Littler, Uli Schopfer, Geoff Holdgate and Christian Ottman

9:10 - 10:30 Anti-InfectivesOne of the greatest health challenges is the emergence of new pathogens and those with resistance to current drugs. This workshop will focus upon what are the emerging pathogens and what are the targets or technologies that are being applied or developed to tackle these challenges. Topics to be included are emerging haemorrhagic viruses (Ebola), diseases with known causative agents with poor treatment (RSV and HBV) and bacterial challenges (gram negative organisms).

Eddy Littler, DomainexKen Powell, Chairman of ReViralSivaramesh Wigneshweraraj, Imperial CollegeDavid Hughes, Chief Technology Officer CNBIOLaura Lane, Warwick Ventures

TIME PANELIST TITLE

10:30 - 11:00 COFFEE BREAK

11:00 - 12:30 Future of HTSIn this panel discussion we will explore some of the forces that will shape the future of HTS, and of lead discovery in general. Experts from big Pharma, Biotec and academia will explore developments in science and technology and partnership models that allow taking advantage of these developments in times of constrained budgets.•Role/Impact of new technologies (CRISPR, iPS, 3D, microfluidics, others…)•Future role of CROs in times of increasingly constraint budgets•Focused vs large scale screening•Target-based, phenotypic and what is next

Ulrich Schopfer, NovartisSteve Rees, AstraZenecaDirk Ullmann, EvotecPhil Gribbon, EU-OPENSCREEN Fraunhofer IME GermanyPeter Roevens, Janssen

12:30 - 14:00

14:00 - 15:00


PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for respiratory inflammation


12:30 - 14:00 Geoff Holdgate, AstraZenecaJon Hutchinson, GSKChris Abell, University of CambridgeJohn Unitt, Sygnature DiscoveryMichelle Heathcote, ProximagenWalter Ward, Walter Ward Consultancy & Training

15:00 - 16:30 Protein - Protein Interaction Drug DiscoveryMore than 300,000 Protein-Protein Interactions (PPIs) can be found in human cells. Specific and potent modulation of PPIs would tremendously enlarge the "druggable genome" enabling novel ways of drug discovery for essentially every human disease. We have seen great progress in the last 10 - 15 years in the identification and development of PPI modulators, however, PPIs are still considered as one of the most demanding targets in drug discovery. In this forum we will discuss recent progress, medicinal chemistry and clinical challenges and the future prospects of PPI modulators to fulfill their tremendous potential as novel therapeutic agents.

Christian Ottman, Technical University, EindhovenDavid Thomas, Traffick Therapeutiques, Inc.Mike Waring, AstraZeneca/Newcastle UniversityTom Crabbe, UCBAlicia Higueruelo, TIMBAL-DBOlivier Sperandio, iPPI-DB

16:30 - 17:00 CLOSE OF CONFERENCE - with prize draw


Room: Coalport

Enzymology Used Throughout Drug DiscoveryThe combination of activity data from biochemical assays, binding data from biophysical methods and structural information has allowed new perspectives for the application of enzymology in drug discovery. In addition to discussing traditional approaches including the development of multi-substrate assays and the characterisation of pan assay interference compounds, which are crucial activities for optimizing assay readout and the identification of true hits, this forum will also explore the characterisation of slow-binding and irreversible compounds, as there is now an increasing interest in guiding the development of structure activity relationships by means of binding kinetics and residence times.

POSTER COMPETITION

TECHNOLOGY PRIZE

SLAS YOUNG SCIENTIST PRIZE

Every year at ELRIG Drug Discovery we get a fantastic range of Posters presented. We invite YOU, the delegates, to vote for what you think is the best poster.

Simply fill in your choice on the voting form in your programme and return it to the ELRIG registration desk.The winner will be announced in the closing address ( Ironbridge, 16:30, Thurday 3rd September). Votes returned by 3pm on Thursday 3rd will be entered into a PRIZE DRAW – also made at the closing address. (Please note you need to be there in person to win).

Please have a good look around the exhibition: it’s the exhibitors’ support that keeps ELRIG events free to attend.

We invite YOU, the delegates, to vote for what you think is the best technology being shown in the exhibition.

Fill in your choice on the voting form in your programme and return it to the ELRIG registration desk. The winner will be announced in the closing address (Ironbridge, 16:30, Thur 3rd). Votes returned by 3pm on Thurs 3rd will be entered into a PRIZE DRAW – also made at the closing address. (Again please note that you need to be there to win).

The winner will be invited to present and participate in the Student Poster Competition at the 4th SLAS Annual Conference and Exhibition, SLAS2016, January 23-27, 2016 at the San Diego Convention Centre, SanDiago, California, USA.

SLAS Young Scientist Award winners receive a US$500 cash prize, roundtrip economy airfare, shared hotel accommodation and conference registration for SLAS2016.

Eligibility: Applicants should ideally be a student or within the first five years of their professional scientific research career.

Judging: Will be by a panel of eminent scientists appointed by SLAS and ELRIG. Judging will take place during the whole event, although judges may well (anonymously) come by and chat with you during the official Poster Session from 16:30 to 18:00 on Wednesday September 2. So do your best to be there!

Presentation of the award: Will take place at the conference closing ceremony, and be announced in the ELRIG and SLAS news media.

Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at ELRIG Drug Discovery 2015.

How to enter

1. Posters must have already been submitted, accepted, and on the list for ELRIG DD’15.2. Come to the ELRIG registration Desk and tell us your poster number. Do this before 16:00 on Wednesday September 2 ( i.e. before the poster session starts).

www.elrig.org

European LaboratoryResearch & Innovation Group

THE ELRIG TECHNOLOGY PRIZE

Please vote for what you think is the most interesting / innovative technology you have seen at the exhibition.

Company:

Technology:

THE ELRIG POSTER PRIZE

Please vote for what you think is the most interesting poster you have seen at this event.

Poster Number:

VOTING

All votes will be entered into a prize draw for a Samsung Galaxy Tablet at the closing session

Name:

Company:

Mobile No:

E-mail:

Please return forms to the ELRIG desk by3 PM ON DAY 2 - Thank you!

DRUG DISCOVERY ‘15

2ND - 3RD SEPTEMBER 2015

TELFORD INTERNATIONAL CONFERENCE CENTRE

NETWORKING

OUR MOBILE APP - ‘ELRIG’

Drug Discovery 2015 is an excellent way to network with like - minded individuals. There are a number of ways you can do this:

• Download our free App : “ELRIG” ( iOs or Android ) ~~/QR code~~ • Complete your profile • Open the DD’15 event • Now – enter the “Networking Form” • There are discussion groups for each session topic, or create a new one: join in! • View the delegates • The “Search” button will find anyone connected with the search words you enter • You can contact people by e-mailing from within the app. Or, you can meet in person in the Networking Zone. There are café tables in the “Networking Zone” which are flagged for each session topic.

All our event information in the palm of your hand for iOS or Android

Free to download :• Programme ( searchable )• Speakers, Biogs, Abstracts• Exhibitors Guide• Posters Guide

• NETWORK • Delegates List • Intelligent Search function • Contact via e-mail • Networking Discussion Forum

Download the app using the QR code.

WI-FI is free at the venue:

Network: TICUK ( upper case )Username: elrig ( lower case )Password: 2015

DRINKS RECEPTION

DRAGON’S DENS

Wine, beer, soft drinks, & nibbles will be served in the Exhibition Hall, giving delegates a chance to mix, chat, network and talk to the exhibitors.Watch the Dragon’s Den on the set in the main hall.

TWO drinks tickets each are provided in your delegate bag : exchange these for your choice of drinks from the servers.

With thanks to our drinks reception sponsor:

Come and hear real entrepreneurs from the show pitch new businesses and products to our panel of expert, ‘Dragons’ - the only thing that’s not real is the money on the table.

“Entertaining & informative”


Exhibition Hall - 17:00 - 18:00


Exhibition Hall - 17:00 - 18:00

EXHIBITORS

INNOVATION ZONE

BioTek Instrumentswww.biotek.com

BlueCatBio GmbHwww.bluecatbio.com

Bigneatwww.bigneat.co.uk

Abcam Plcwww.abcam.com

AstraZenecawww.astrazeneca.co.uk

Axol Bioscience Ltdwww.axolbio.com

BMG LABTECH Ltdwww.bmglabtech.com

Caltag Medsystems Ltdwww.caltagmedsystems.co.uk

Cambridge Biosciencewww.bioscience.co.uk

Cellectricon ABwww.cellectricon.com

Cellular Dynamics International www.cellulardynamics.com

Essen BioScience www.essenbio.com

Formulatrix, Incwww.formulatrix.com

Gilson Scientific Ltdwww.gilsonuk.com

Horizon Discoverywww.horizondiscovery.com

INTEGRA Bioscienceswww.integra-biosciences.com

IntelliCyt Corporationwww.intellicyt.com

Nexcelom BioScience Ltdwww.nexcelom.com

Peak Analysis and Automationwww.paa-automation.com

PerkinElmerwww.perkinelmer.com

Phasefocuswww.phasefocus.com

Promega UK Ltdwww.promega.co.uk

Sigma-Aldrich www.sigmaaldrich.com

Chemometec A/Swww.chemometec.com

HSC Pharmawww.hcs-pharma.com

Celenyswww.celenys.com

MIP Diagnostics Limited

N8 Researchwww.n8research.org.uk

Quantacellwww.quantacell.com

SAL Scientificwww.salscientific.com

The Research Networkwww.theresearchnetwork.co.uk

Tigris Biosciencewww.tigrisbioscience.com

4titude Limitedwww.4ti.co.uk

Agilent Technologieswww.agilent.com

AMS Biotechnology (Europe)www.amsbio.com

Andrew Alliancewww.andrewalliance.com

Aptamer Group Limitedwww.aptamergroup.co.uk

Beckman Coulter UK Limitedwww.beckmancoulter.com

Cell Signaling Technologywww.cellsignal.com

Cisbio Bioassayswww.cisbio.com

Contained Air Solutionswww.containedairsolutions.co.uk

Corning Life Scienceswww.corning.com/lifesciences

Dotmatics Limitedwww.dotmatics.com

Dundee University Drug Discovery Unitwww.drugdiscovery.dundee.ac.uk

EasyFairswww.easyfairs.com

Eurofins Pharma Discovery www.essenbio.com

Eventflo www.myeventflo.com

Genedatawww.genedata.com

Greiner Bio-One Ltdwww.greinerbiooine.com

Hamamatsu Phonics UK Ltdwww.hamamatsu.com

Hamilton Robotics Ltdwww.hamiltonrobotics.com

HighRes Biosolutions Ltdwww.highresbio.com

IKKO-ZU Corporationwww.bioscience-ik.com

Lab Services bvwww.lab-services.nl/

Labcytewww.labcyte.com

Lablogic Systems Ltdwww.lablogic.com

Luminexwww.luminexcorp.com

Miltenyl Biotec GmbHwww.miltenyibiotec.com

Molecular Devices (UK) Ltdwww.moleculardevices.com

NanoTemper Technologies Ltdwww.nanotemper-technologies.com

Sartorius Stedim Biotechwww.tapbiosystems.com

SLAS www.slas.org

Sophion www.biolinscientific.com/sophion

Tecan www.tecan.com

Stratech Scientific Ltd www.stratech.co.uk

Sygnature Discovery www.sygnaturediscovery.com

Titian Software Ltdwww.tition.co.uk

Venomtech Ltdwww.venomtech.co.uk

Zinsser Analytic GmbHwww.zinsser-analytic.com

DRUG DISCOVERY SPONSORS 2016

LANGTON HOWARTH CHALLENGE

EVENT SPONSORS

MEDIA PARTNERS

PARTNERS

WIN WIN WIN!!!

Be sure to visit Langton Howarth in the recruitment zone where we can discuss your hiring requirements and great opportunities available RIGHT NOW as well as testing your reactions on our interactive game where you could win a super car track day!

FUTURE ELRIG MEETINGS

Make sure you are part of these events. Book your place NOW!For more information please contact the ELRIG team:

Email: [email protected] Tel: +44 (0)1904 405 177 Web: www.elrig.org

Become part of the UK’s most innovative life science network

4th - 5th November 2015ELRIG ‘Pop-Up’ at Lab InnovationsNEC, Birmingham, UK

11th November 2015Mass SpectrometryLakeside Conference Centre, York, UK

23rd March 2016Research & Innovation ‘16Trent Vineyard, Nottingham, UK

4th May 2016Robotics & AutomationFesto, Northampton, UK

14th - 15th June 2016Recombinant Protein TechnologyAstraZeneca. Molndal, Sweden

1st - 2nd September 2016Drug Discovery ‘16Telford International Conference Centre, UK

22nd - 23rd November 2016Pharmaceutical Flow Cytometry & ImagingGSK, Stevenage, UK

Documents

DRUG DISCOVERY 15 - ELRIG · Bedside to Bench Target Identification and Target Engagement: Applications in Drug Discovery The Kinetics of Drug-Receptor Binding: Why It Is Important